MedTrace Logo

Re-examination Study For Varivax (V210-059 AM2)

NCT01062061 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 754

Last updated 2015-09-04

Study results available
· View outcomes & findings →

Summary

This survey is conducted for preparing application materials for re-examination under the Korean Pharmaceutical Affairs Laws and its Enforcement Regulation; its aim is to reconfirm the clinical usefulness of VARIVAX through collecting the safety information according to the Re-examination Regulation for New Drugs.

Conditions

  • Varicella

Interventions

BIOLOGICAL

VARIVAX™

Attenuated live varicella vaccine

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Eligibility

Min Age
12 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2012-05-31
Completion
2012-05-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01062061 on ClinicalTrials.gov